Toward the next generation of CAR T cell therapies for cancer.

Seven FDA-approved CAR T cell products for 15 indications demonstrate the therapy's established effectiveness in cancer treatment.

• Why it matters: Extending efficacy to solid tumors and reducing manufacturing costs are critical challenges that impact patient access and the broader application of CAR T cell therapies.
• What they did: The review summarizes clinical lessons from extensive experience with commercial CAR T cells and trials, focusing on three development waves: multi-engineered and logic-gated CAR T cells, rational combination strategies, and in vivo CAR T cell generation.
• The result: Integrating clinical insights with emerging strategies highlights successes and gaps, guiding the design of next-generation therapies to overcome current barriers.